Welcome to Markets Desk, your midday read on what's moving and why.
Ten-year Treasury yields are pressing higher, and the five percent level is drawing serious attention. This isn't simply a Federal Reserve story anymore — it reflects deeper structural forces, including deficit concerns, term premium repricing, and a bond market that's increasingly skeptical of long-term fiscal discipline. That threshold matters because it raises borrowing costs across mortgages, corporate credit, and equity valuations simultaneously.
Shifting to equities, utility stocks are getting hit hard today, with PG&E leading the declines after California lawmakers passed wildfire liability legislation that analysts say prioritizes victim protections without offering investors meaningful new safeguards. That asymmetry is exactly what the market is pricing in — the downside risk stays on the shareholder, and the sector is repricing accordingly.
On the policy front, the Trump administration is reportedly close to announcing drug pricing agreements with nearly a dozen pharmaceutical companies, extending its push to tie domestic prices to cheaper international benchmarks. Watch how biotech and large-cap pharma trade into any formal announcement — the market will be parsing whether these deals carry real enforcement teeth or remain largely symbolic.
That's the tape. Markets Desk, signing off the floor.
